OGI vs. SANA, SEPN, TYRA, CRON, REPL, IMTX, AVDL, PLRX, BCAX, and PRTA
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Sana Biotechnology (SANA), Septerna (SEPN), Tyra Biosciences (TYRA), Cronos Group (CRON), Replimune Group (REPL), Immatics (IMTX), Avadel Pharmaceuticals (AVDL), Pliant Therapeutics (PLRX), Bicara Therapeutics (BCAX), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry.
Organigram vs.
Organigram (NASDAQ:OGI) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking.
Sana Biotechnology has a consensus target price of $14.25, suggesting a potential upside of 350.95%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Organigram.
Organigram received 178 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 70.71% of users gave Organigram an outperform vote while only 60.61% of users gave Sana Biotechnology an outperform vote.
34.6% of Organigram shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 0.1% of Organigram shares are held by insiders. Comparatively, 31.1% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Sana Biotechnology has a net margin of 0.00% compared to Organigram's net margin of -28.58%. Organigram's return on equity of -11.68% beat Sana Biotechnology's return on equity.
Organigram has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Sana Biotechnology has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
In the previous week, Sana Biotechnology had 2 more articles in the media than Organigram. MarketBeat recorded 5 mentions for Sana Biotechnology and 3 mentions for Organigram. Organigram's average media sentiment score of 0.39 beat Sana Biotechnology's score of 0.25 indicating that Organigram is being referred to more favorably in the media.
Organigram has higher revenue and earnings than Sana Biotechnology. Organigram is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Organigram beats Sana Biotechnology on 9 of the 17 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
This page (NASDAQ:OGI) was last updated on 1/20/2025 by MarketBeat.com Staff
